Exelixis Inc

Type: Company
Name: Exelixis Inc
Nationality: United States
Web Address: http://www.exelixis.com/
First reported Apr 22 2014 - Updated Apr 22 2014 - 1 reports

BioNews – 04/22/14

  Top News Headline Company Type Exelixis, Inc. (EXEL) To Release First Quarter 2014 Financial Results On Thursday, May 1, 2014 Exelixis Financials VCs Wager $243 Million On San Diego Startups In Q1 n/a Funding Google adds UCSF geneticist ... [Published eClinical Trends - Apr 22 2014]
First reported Apr 22 2014 - Updated Apr 22 2014 - 1 reports

Exelixis, Inc. To Release First Quarter 2014 Financial Results On Thursday, May 1, 2014

Exelixis, Inc. (NASDAQ: EXEL) will release its first quarter 2014 financial results on Thursday, May 1, 2014 after the markets close. The announcement will be followed by a live conference call and webcast at 5:00 p.m. EDT/ 2:00 p.m. PDT. During the presentation, ... [Published BioSpace - Apr 22 2014]
Entities: Exelixis Inc
First reported Apr 18 2014 - Updated Apr 18 2014 - 1 reports

1 of These 3 Cratering Biotechs is a Buy

At the start of the year, the theme seemed to be that biotech was in for another banner year, propelled by a suite of newly launch drugs that would go on to become blockbusters. These rosy prognostications were made despite broad-based biotech funds like ... [Published Motley Fool Discussion Boards - Apr 18 2014]
First reported Apr 14 2014 - Updated Apr 15 2014 - 3 reports

Exelixis Looks to Continue to Trade Below its Annual-Low Share Price Today

Written on Tue, 04/15/2014 - 12:27pmBy Shiri GuptaShares of Exelixis ( NASDAQ:EXEL ) traded today at $3.17, breaking its 52-week low. So far today approximately 2.7 million shares have been exchanged, as compared to an average 30-day volume of 6.8 million ... [Published Comtex SmarTrend - Apr 15 2014]
First reported Apr 03 2014 - Updated Apr 03 2014 - 2 reports

Are These 3 Biotechs Bad News Buys?

March wasn't kind to many of biotech's hottest names. From Geron (NASDAQ: GERNGeron suffered perhaps the worst loss of the month by plunging more than 50% after the FDA placed a clinical hold on the company's developmental drug Imetelstat, but it was ... [Published Motley Fool - Apr 03 2014]
First reported Mar 31 2014 - Updated Mar 31 2014 - 2 reports

Hot Stock: Exelixis, Shares Gain 5.2% (EXEL)

Written on Mon, 03/31/2014 - 11:42amBy David DiazExelixis ( NASDAQ:EXEL ) is one of today's best performing low-priced stocks, up 5.2% to $3.56 on 1.6x average daily volume. Exelixis has traded 7.4 million shares thus far today, vs. average volume of ... [Published Comtex SmarTrend - Mar 31 2014]
First reported Mar 29 2014 - Updated Mar 29 2014 - 2 reports

Why Red Hat, Caesars Entertainment, and Exelixis Tumbled Today

Favorable economic news helped send the stock market higher despite the usual pre-weekend jitters on Wall Street, as larger gains earlier in the day gave way to traders once again choosing not to hold onto positions in light of geopolitical uncertainties ... [Published Motley Fool - Mar 29 2014]
First reported Mar 27 2014 - Updated Mar 28 2014 - 3 reports

Is This the Year Exelixis Excels?

We continue to believe that Cometriq has a 50% chance of success in the trial, and we are maintaining our $7.50 fair value estimate and no-moat rating for Exelixis. While the stock had been trading around our fair value estimate, we think the recent sell-off ... [Published Morningstar.com - Mar 28 2014]
First reported Mar 25 2014 - Updated Mar 26 2014 - 11 reports

Exelixis Plunges Most Since 2011 as Drug Trial Must Continue

(Updates with comments from CEO in third paragraph.)March 26 (Bloomberg) -- Exelixis Inc. plunged the most in almost 2 1/2 years after the biotechnology company said trials of its prostate cancer drug wouldn’t end early.Analysts anticipated the study ... [Published Washington Post - Mar 26 2014]
First reported Mar 26 2014 - Updated Mar 26 2014 - 2 reports

Exelixis Stock Price Down 36.2% on Analyst Downgrade (EXEL)

Exelixis (NASDAQ:EXEL)’s share price fell 36.2% on Wednesday after Credit Suisse lowered their price target on the stock from $6.00 to $5.00, reports. The stock traded as low as $4.05 and last traded at $4.11, with a volume of 33,141,488 shares trading ... [Published American Banking News - Mar 26 2014]
First reported Mar 25 2014 - Updated Mar 26 2014 - 4 reports

EU approval for Cometriq in medullary thyroid carcinoma25-03-2014

The European Commission has approved Cometriq (cabozantinib), a drug for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma (MTC), from Swedish Orphan Biovitrum (STO: SOBI) and partner ... [Published Pharma Letter - Mar 26 2014]
First reported Mar 25 2014 - Updated Mar 25 2014 - 11 reports

European Commission approves Exelixis COMETRIQ for treatment of progressive metastatic MTC

Exelixis, Inc. (NASDAQ:EXEL) today announced that the European Commission has approved COMETRIQ® (cabozantinib) for the treatment of adult patients with progressive, unresectable locally advanced ... ... [Published Big News Network - Mar 25 2014]

Quotes

NEXT ARTICLE More From BioPortfolio on "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014"
NEXT ARTICLE More From BioPortfolio on "Exelixis to Release First Quarter 2014 Financial Results on Thursday, May 1, 2014"
...is that the market believes that cabozantinib will have trouble competing against more established prostate cancer drugs like Johnson & Johnson "s Zytiga without strong evidence that the drug has a stellar efficacy profile. Indeed, the prostate cancercancer drug market has seen a number of newcomers of late, some of whom have struggled in this crowded space. That said, I believe Exelixis is now a bargain following this dramatic sell-off and is set to rebound. My thinking is simple: Some of the worst-selling prostate cancer drugs still see sales in the hundreds of millions and Exelixis" market cap has fallen to a mere $600 million...
"FLT3 inhibitors are classified as Type I or Type II inhibitors. These two classifications are distinguished based on their relative affinities and mechanism of binding to phosphorylated and non-phosphorylated receptor sites. Type I inhibitors recognize the active conformation of kinases. This conformation is conducive to phosphotransfer. Type I inhibitors are generally composed of a heterocyclic ring system. See Liu , Y and N Gray. Rational design of inhibitors that bind to inactive kinase conformations. Nature Chem. Biol. 2006; 2:358-354. Examples of Type I FLT3 inhibitors include Crenolanib besylate and Midostaurin. See Muralidhara C , Ramachandran A, Jain V Crenolanib, a novel type I, mutant-specific inhibitor of class III receptor tyrosine kinases, preferentially binds to phosphorylated kinases. Cancer Research . 2012; 72 (8 Supplement): 3683; J Cools, et al. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. Cancer Res. 2004; 64:6385-6389. Resistant mutations that render the kinase of the receptor tyrosine kinase constitutively phosphorylated could potentially be sensitive to type I inhibitors that have greater affinity for the phosphorylated kinase."

More Content

All (185) | News (136) | Reports (0) | Blogs (46) | Audio/Video (0) | Fact Sheets (0) | Press Releases (3)
sort by: Date | Relevance
Exelixis Sets Date to Release First Quarter Res... [Published Individual.com - 8 hours ago]
BioNews – 04/22/14 [Published eClinical Trends - Apr 22 2014]
Exelixis, Inc. To Release First Quarter 2014 Fi... [Published BioSpace - Apr 22 2014]
Metastatic Hormone Refractory Castration Resist... [Published BioPortfolio - Apr 22 2014]
Exelixis to Release First Quarter 2014 Financia... [Published BioPortfolio - Apr 21 2014]
Exelixis to Release First Quarter 2014 Financia... [Published Business Wire Health News - Apr 21 2014]
1 of These 3 Cratering Biotechs is a Buy [Published Motley Fool Discussion Boards - Apr 18 2014]
Ian Read becomes PhRMA board chairman; Ken Fraz... [Published Center Watch - Apr 18 2014]
Exelixis Looks to Continue to Trade Below its A... [Published Comtex SmarTrend - Apr 15 2014]
Exelixis Sees Large Growth in Short Interest (E... [Published Zolmax News - Apr 15 2014]
Exelixis: The Losing Streak Continues (EXEL) [Published Comtex SmarTrend - Apr 14 2014]
Pfizer’s Ian Read Becomes PhRMA Board Chairman;... [Published OSIX News - Apr 11 2014]
Patent Application Titled "Method of Inhibiting... [Published HispanicBusiness.com - Apr 10 2014]
3 Stocks Under $10 to Trade for Breakouts [Published The Street Latest - Apr 09 2014]
Leerink Swann Lowers Exelixis Price Target to $... [Published American Banking News - Stock Ratings - Apr 07 2014]
European Commission Approves Exelixis Inc.’s Th... [Published Accesswire - Apr 04 2014]
Why I Bought Exelixis [Published Motley Fool Discussion Boards - Apr 04 2014]
Are These 3 Biotechs Bad News Buys? [Published Motley Fool - Apr 03 2014]
Are These 3 Biotechs Bad News Buys? [Published Motley Fool Discussion Boards - Apr 03 2014]
Short Interest in Exelixis Decreases By 3.0% (E... [Published American Banking News - Forex - Apr 03 2014]
Biotech Stock Roundup: Biogen Drug Approved, Ex... [Published Zacks.com - Apr 02 2014]
Exelixis Continues On [Published Motley Fool Discussion Boards - Apr 01 2014]
Biotechs Are Crashing: Here's This Week's Actio... [Published StreetAuthority - Mar 31 2014]
Hot Stock: Exelixis, Shares Gain 5.2% (EXEL) [Published Comtex SmarTrend - Mar 31 2014]
Stock to Watch: Exelixis Up 5.2% (EXEL) [Published Individual.com - Mar 31 2014]
What Charts Say About Exelixis, Inc. (NASDAQ:EX... [Published Live Trading News - Mar 31 2014]
Inovio Pharmaceuticals Inc. (NYSEMKT:INO) To Co... [Published Live Trading News - Mar 31 2014]
Neutral Trend For MannKind Corporation (NASDAQ:... [Published Live Trading News - Mar 31 2014]
Which Biotech Blow-Up Is a Bad-News Buy? [Published Motley Fool Discussion Boards - Mar 30 2014]
5 of Last Week's Biggest Losers [Published Motley Fool - Mar 30 2014]
1 2 3 4 5 6 7
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
BioNews – 04/22/14 [Published eClinical Trends - Apr 22 2014]
  Top News Headline Company Type Exelixis, Inc. (EXEL) To Release First Quarter 2014 Financial Results On Thursday, May 1, 2014 Exelixis Financials VCs Wager $243 Million On San Diego Startups In Q1 n/a Funding Google adds UCSF geneticist ...
Exelixis to Release First Quarter 2014 Financia... [Published Business Wire Health News - Apr 21 2014]
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) will release its first quarter 2014 financial results on Thursday, May 1, 2014 after the markets close. The announcement will be followed by a live conference call and webcast ...
Exelixis Enters the Danger Zone [Published 24/7 Wall St. - Mar 26 2014]
Exelixis may have a while longer before it gets to be a serious revenue stage company. Its stock was crushed on Wednesday, and the company has lost its $1 billion market cap. ...
Exelixis Provides Update on Ongoing COMET-1 Pha... [Published Business Wire Health News - Mar 25 2014]
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) announced that the Independent Data Monitoring Committee (IDMC) notified the company today that a planned interim analysis of the COMET-1 phase 3 pivotal trial has been completed, ...
Exelixis Receives Approval for COMETRIQ® (Caboz... [Published Business Wire Health News - Mar 25 2014]
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) today announced that the European Commission has approved COMETRIQ® (cabozantinib) for the treatment of adult patients with progressive, unresectable locally advanced or metastatic ...
1 2 3 4 5 6 7 8 9 10

Press Releases

sort by: Date | Relevance
Cometriq® approved in Europe for the treatment ... [Published GlobeNewswire: Acquisitions News - Mar 25 2014]
Pre-Market Pulse - Health Care Sector Stocks --... [Published Financial Services - Mar 24 2014]
Clinical Study Results, Pending Applications, T... [Published Financial Services - Dec 25 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.